Hepion sells Rencofilstat assets to Panetta for nominal fee; stockholders get CVR milestones

Hepion Pharmaceuticals, Inc.

Sold all patent assets, knowhow, clinical data, and drug product for Rencofilstat to Panetta Partners for nominal amount.
Stockholders receive CVR: $500K upon FDA approval of first NDA for Rencofilstat.
Additional CVR payments: $1M if net sales exceed $350M; $3M if net sales exceed $750M.

item 1.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.